Top Quality Peptide Raw Goserelin Acetate 145781-92-6
Product Description
Goserelin Acetate
Sequence: Pyr-His-Trp-Ser-Tyr-D-Ser(tBu)-Leu-Arg-Pro-Aza-Gly-NH2
Cas No.: 145781-92-6
Molecular Formula: C61H88N18O16
Molecular Weight: 1269.4
Purity (HPLC): 98.0%min.
Appearance: White powder
Single Impurity (HPLC): 0.5%max
Amino Acid Composition: ±10% of theoretical
Peptide Content (N%): ≥80.0%
Water Content(Karl Fischer): ≤8.0%
Acetate Content(HPIC): ≤10.0%
MS (ESI): Consistent
Mass Balance: 95.0~105.0%
Goserelin Basic Info
Payment Terms:T/T, Western Union, Money Gram, Bitcoin
Model NO.: 145781-92-6
Customized: Customized
Suitable for: Adult
Purity: >99%
Shelf Life: Two Years
Trademark: WuMeiTech
Specification: 100% Qualified
Powder: Yes
Shipment Way: EMS, HK Post, DHL, TNT, UPS, FedEx, Aramex
Storage: Keep It Cool
Transport Package: Discreet and Perfect
Origin: China
Top Quality Peptide Raw Goserelin Acetate 145781-92-6
Goserelin Product Description:
Goserelin is a synthetic analogue of a naturally occurring luteinizing-hormone releasing hormone (LHRH). Bioavailability is almost complete. Goserelin is poorly protein bound and has a serum elimination half-life of two to four hours in patients with normal renal function. The half-life increases with patients with impaired renal function. There is no significant change in pharmacokinetics in subjects with liver failure. After administration, peak serum concentrations are reached in about two hours. It rapidly binds to the LHRH receptor cells in the pituitary gland thus leading to an initial increase in production of luteinizing hormone and thus leading to an initial increase in the production of corresponding sex hormones. This initial flare may be treated by co-prescribing/co-administering an androgen receptor antagonist such as bicalutamide (Casodex). Eventually, after a period of about 14-21 days, production of LH is greatly reduced due to receptor downregulation, and sex hormones are generally reduced to castrate levels
Goserelin Product Application:
Goserelin acetate is used to treat hormone-sensitive cancers of the breast(in pre- and peri-menopausal women) and prostate, and some benign gynaecological disorders (endometriosis, uterine fibroids and endometrial thinning). In addition, goserelin is used in assisted reproduction and in the treatment of precocious puberty. It may also be used in the treatment of male-to-female transgender people and is favoured above other anti-androgens in some countries, such as the UK. It is available as a 1-month depot and a long-acting 3-month depot.
Goserelin Side Effects:
Goserelin acetate may cause a temporary increase in bone pain and symptoms of prostatic cancer during the first few weeks of treatment. This is known as the tumour flare effect, and is the result of an initial increase inluteinizing hormone production, before the receptors are desensitised and hormonal production is inhibited. The symptoms will disappear, with hormonal inhibition. It is therefore advisable to co-treat with anantiandrogen during the first 2-3 weeks of goserelin treatment, particularly in patients with pre-existing bone symptoms.
